Claims
- 1. A method of treating bronchospasm in a patient with reversible obstructive airway disease, comprising administering to said patient a therapeutically effective amount of optically pure R-(-) albuterol.
- 2. A method according to claim 1, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.
- 3. A method according to claim 1, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.
- 4. A method according to claim 1, wherein the optically pure R(-) albuterol is administered by inhalation.
- 5. A method according to claim 4, wherein the optically pure R(-) albuterol is administered in an amount of about 30 .mu.g to about 90 .mu.g.
- 6. A method according to claim 1, wherein the optically pure R(-) albuterol is administered orally.
- 7. A method according to claim 6, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.
- 8. A method according to claim 6, wherein the optically pure R(-) albuterol is administered as a tablet, capsule or syrup.
- 9. A method according to claim 7, wherein the optically pure R(-) albuterol is administered as a syrup.
- 10. A method of preventing bronchospasm in a patient with reversible obstructive airway disease, comprising administering to said patient a therapeutically effective amount of optically pure R-(-) albuterol.
- 11. A method according to claim 10, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.
- 12. A method according to claim 10, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.
- 13. A method according to claim 10, wherein the optically pure R(-) albuterol is administered by inhalation.
- 14. A method according to claim 13, wherein the optically pure R(-) albuterol is administered in an amount of about 30 .mu.g to about 90 .mu.g.
- 15. A method according to claim 10, wherein the optically pure R(-) albuterol is administered orally.
- 16. A method according to claim 15, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.
- 17. A method according to claim 15, wherein the optically pure R(-) albuterol is administered as a tablet, capsule or syrup.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation of our prior copending application Ser. No. 09/200,541, filed Nov. 25, 1998, which is a continuation of application Ser. No. 09/063,551, filed Apr. 21, 1998, now U.S. Pat. No. 5,844,002, which was a continuation of application Ser. No. 08/691,604, filed Aug. 15, 1996, now U.S. Pat. No. 5,760,090, which was a continuation of application Ser. No. 08/335,480, filed Nov. 7, 1994, now U.S. Pat. No. 5,547,994, which was a continuation of application Ser. No. 08/163,581, filed Dec. 7, 1993, now U.S. Pat. No. 5,362,755, which was a continuation of application Ser. No. 07/896,725, filed Jun. 9, 1992 now abandoned, which was a continuation of application Ser. No. 07/461,262, filed Jan. 5, 1990, now abandoned.
Foreign Referenced Citations (3)
Number |
Date |
Country |
2128258 |
Jan 1983 |
DEX |
1298494 |
Jan 1971 |
GBX |
2 255 503 |
Jan 1992 |
GBX |
Non-Patent Literature Citations (11)
Entry |
Tan et al. "Stereoselective Disposition of Salbutamol Enantiomers . . . " Clin. Chem. 33, 1026 (1987). |
Brittain et al. "Some observations on the .beta.-adrenoceptor agonist . . . " Br. J. Pharmac. 48, 144-147 (1973). |
Hartley et al. "Absolute Configuration of the Optical Isomers of Salbutamol" J. Med. Chem. 12, 995 (1971). |
Hawkins et al. "Relative Potency of (-)- and (.+-.) -Salbutamol on Guinea Pig . . . " J. Med. Chem. 16, 856-857 (1973). |
Buckner et al. "Studies on the Effects of Enantiomers of Soterenol, Trimetoquinol . . . " J. Pharm. Exp. Ther. 189, 616-625 (1974). |
Passowicz-Muszynska E. "Effect on beta adrenergic receptors of tachyphylaxis . . . " Index Medicus 91:164287. |
Pauwels "Effect of corticosteroids on the action of sympathomimetics" Index Medicus 86:051970. |
Chapman et al. "An anomalous effect of salbutamol in sensitised guinea pigs" Brit. J. Pharmacol 99, 66P (1990). |
Morley et al. "Effects of (+) and racemic salbutamol on airway responses in the guinea pig" Brit. J. Pharmacol. 104, 295P (1991). |
Chapman et al. "Racemic mixtures at root of worsening symptoms? Active enantiomers . . . " TIPS 13, 231-232 (1992). |
Muittari et al. "Comparison of acute bronchodilator effects of oral salbutamol, . . . " Chem. Abstr. 89: 123259m (1978). |
Continuations (7)
|
Number |
Date |
Country |
Parent |
200541 |
Nov 1998 |
|
Parent |
063551 |
Apr 1998 |
|
Parent |
691604 |
Aug 1996 |
|
Parent |
335480 |
Nov 1994 |
|
Parent |
163581 |
Dec 1993 |
|
Parent |
896725 |
Jun 1992 |
|
Parent |
461262 |
Jan 1990 |
|